Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome

Fertility and Sterility

Volumn 73, Issue 6, 2000, Pages 1149-1154

  Kolodziejczyk, Beata ^a   Duleba, Antoni J ^b   Spaczynski, Robert Z ^a   Pawelczyk, Leszek ^a  

^a Dept Gynecol Obstet Karol M   (Poland)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hyperinsulinemia; Metformin; PCOS

Indexed keywords

GONADOTROPIN; INSULIN; METFORMIN; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN C; THYROXINE;

ACNE; ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HIRSUTISM; HORMONE BLOOD LEVEL; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; MENSTRUATION; OUTCOMES RESEARCH; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; FASTING; FEMALE; HUMANS; HYPERANDROGENISM; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; POLYCYSTIC OVARY SYNDROME; PROSPECTIVE STUDIES; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE;

EID: 0034111902     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(00)00501-X     Document Type: Article

References (40)

1. Tjaden B. Polycystic ovary syndrome relationship to growth hormone, insulin-like growth factor-1, and insulin . Curr Opin Obstet Gynecol. 6:1994;279-283.
2. Poretsky L. On the paradox of insulin-induced hyperandrogenism in insulin-resistant states. Endocr Rev. 12:1991;3-13.
3. Nestler J.E., Strauss J.F. Insulin as an effector of human ovarian and adrenal steroid metabolism. Endocrinol Metab Clin North Am. 20:1991;807-821.
4. Franks S. Polycystic ovary syndrome. N Engl J Med. 333:1995;853-861.
5. Holte J. Disturbances in insulin secretion and sensitivity in women with the polycystic ovary syndrome. Baillieres Clin Endocrinol Metab. 10:1996;221-247.
6. Lobo R.A. Polycystic ovary syndrome/hyperandrogenic chronic anovulation. Adv Endocrinol Metab. 6:1995;167-191.
7. Dunaif A., Graf M., Mandeli J., Dobrjansky A. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab. 65:1987;499-507.
8. Nestler J.E., Jakubowicz D.J., Evans W.S., Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med. 338:1998;1876-1880.
9. Velázquez E.M., Mendoza S., Hamer T., Sosa F., Glueck C.J. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 43:1994;647-654.
10. Velázquez E., Acosta A., Mendoza S.G. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol. 90:1997;392-395.
11. Carmina E., Koyama T., Chang L., Stanczyk F.Z., Lobo R.A. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? Am J Obstet Gynecol. 167:1992;1807-1812.
12. Hoffman D., Klove K., Lobo R. The prevalence and significance of elevated dehydroepiandrosterone sulfate levels in anovulatory women. Fertil Steril. 42:1984;76-81.
13. Azziz R., Black V., Hines G.A., Fox L.M., Boots L.R. Adrenal androgen excess in the polycystic ovary syndrome sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis . J Clin Endocrinol Metab. 83:1998;2317-2323.
14. Gonzales F. Adrenal involvement in polycystic ovary syndrome. Semin Reprod Endocrinol. 15:1997;137-157.
15. Smith S., Ravnikar V.A., Barbieri R.L. Androgen and insulin response to an oral glucose challenge in hyperandrogenic women. Fertil Steril. 48:1987;72-77.
16. Schriock E.D., Buffington C.K., Hubert G.D. Divergent correlations of circulating dehydroepiandrosterone sulfate and testosterone with insulin levels and insulin receptor binding. J Clin Endocrinol Metab. 66:1988;1329-1331.
17. Diamond M.P., Grainger D., Laudaro A.J. Effect of acute physiological elevations of insulin on circulating androgen levels in normal women. J Clin Endocrinol Metab. 72:1991;883-887.
18. Nestler J.E., Usiskin K.S., Barlascini C.O., Welty D.F., Clore J.N., Blackard W.G. Suppression of serum dehydroepiandrosterone sulfate levels by insulin an evaluation of possible mechanism . J Clin Endocrinol Metab. 69:1989;1040-1046.
19. Dunaif A., Graf M. Insulin administration alters gonadal steroid metabolism independent of changes in gonadotropin secretion in insulin-resistant women with polycystic ovary syndrome. J Clin Invest. 83:1989;23-29.
20. Nestler J.E., Clore J.N., Strauss J.F. III, Blackard W.G. The effect of hyperinsulinemia on serum testosterone, progesterone, dehydroepiandrosterone sulfate and cortisol levels in normal women and in a woman with hyperandrogenism, insulin resistance and acanthosis nigricans. J Clin Endocrinol Metab. 64:1987;180-184.
21. DeFronzo R.A., Barzilai N., Simonson D.C. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab. 73:1991;1294-1301.
22. Stumvoll M., Nurjhan N., Perriello G., Dailey G., Gerich J.E. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 333:1995;550-554.
23. Açbay O., Gündogdu S. Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertil Steril. 65:1996;946-949.
24. Ehrmann D.A., Cavaghan M.K., Imperial J., Sturis J., Rosenfield R.L., Polonsky K.S. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 82:1997;524-530.
25. Diamanti Kandarakis E., Kouli C., Tsianateli T., Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol. 138:1998;269-274.
26. Morin Papunen L.C., Koivunen R.M., Ruokonen A., Martikainen H.K. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril. 69:1998;691-696.
27. Thomas P.K., Ferriman D.G. Variation in facial and pubic hair growth in white women. Am J Phys Anthropol. 15:1957;171-180.
28. Legro R.S., Finegood D., Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 83:1998;2694-2698.
29. Nestler J.E., Barlascini C.O., Matt D.W., Steingold K.A., Plymate S.R., Clore J.N. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 68:1989;1027-1032.
30. Dunaif A., Scott D., Finegood D., Quintana B., Whitcomb R. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab. 81:1996;3299-3306.
31. Ehrmann D.A., Schneider D.J., Sobel B.E., Cavaghan M.K., Imperial J., Rosenfield R.L., et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 82:1997;2108-2116.
32. Inzucchi S.E., Maggs D.G., Spollett G.R., Page S.L., Rife F.S., Walton V., et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med. 338:1998;867-872.
33. Bailey C.J., Puah J.A. Effect of metformin and glucose metabolism in mouse soleus muscle. Diabete et Metabolisme. 12:1986;212-218.
34. Conn J.J., Jacobs H.S. Managing hirsutism in gynaecological practice. Br J Obstet Gynaecol. 105:1998;687-696.
35. Velázquez E.M., Mendoza S.G., Wang P., Glueck C.J. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism. 46:1997;454-457.
36. Glueck C.J., Wang P., Fontaine R., Tracy T., Sieve-Smith L. Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism. 48:1999;511-519.
37. Nestler J.E., Beer N.A., Jakubowicz D.J., Colombo C., Beer R.M. Effects of insulin reduction with benfluorex on serum dehydroepiandrosterone (DHEA), DHEA-sulfate, and blood pressure in hypertensive middle-aged and elderly men. J Clin Endocrinol Metab. 80:1995;700-706.
38. Falcone T., Finegood D.T., Fantus I.G., Morris D. Androgen response to endogenous insulin secretion during the frequently sampled intravenous glucose tolerance test in normal and hyperandrogenic women. J Clin Endocrinol Metab. 71:1990;1653-1657.
39. Weber M.M., Auernhammer C.J., Kiess W., Engelhardt D. Insulin-like growth factor receptors in normal and tumorous adult human adrenocortical glands. Eur J Endocrinol. 136:1997;296-303.
40. Fottner C., Engelhardt D., Weber M.M. Regulation of steroidogenesis by insulin-like growth factors (IGFs) in adult human adrenocortical cells IGF-I and, more potently, IGF-II preferentially enhance androgen biosynthesis through interaction with the IGF-I receptor and IGF-binding proteins . J Endocrinol. 158:1998;409-417.